Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs). This is an ASCO Meeting Abstract from the 2021 ASCO ...
Of the 491 patients, 21.2% had HER2-low expression, 30% had HER2 overexpression, and 50% had HER2-negative expression. Among the hormone receptor (HR)–positive patients, 34% had HER2-low expression; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results